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Abstract 
Daily subcutaneous (SC) injections of the investigational drug abaloparatide-SC (80mcg) for 18 
months significantly decrease the risk of vertebral and non-vertebral fracture compared with 
placebo in postmenopausal women. We examined the efficacy of abaloparatide-SC as a 
function of baseline fracture risk, assessed using the FRAX tool.  
Baseline clinical risk factors (age, BMI, prior fracture, glucocorticoid use, rheumatoid arthritis, 
and smoking) were entered into country-specific FRAX models to calculate the 10-year 
probability of major osteoporotic fractures, with or without femoral neck BMD. The 
interaction between probability of a major osteoporotic fracture and treatment efficacy was 
examined by a Poisson regression.  
821 women randomized to placebo and 824 women to abaloparatide-SC, mean age 69 years 
in both groups, were followed for up to 2 years. At baseline, the 10-year probability of major 
osteoporotic fractures (with BMD) ranged from 2.3-57.5% (mean 13.2%). Treatment with 
abaloparatide-SC was associated with a 69% (95%CI: 38, 85%) decrease in major osteoporotic 
fracture (MOF) and a 43% (95%CI: 9, 64%) decrease in any clinical fracture compared to 
placebo.  For all outcomes, hazard ratios tended to decrease (i.e., greater efficacy) with 
increasing fracture probability. Whereas the interaction approached significance for the 
outcome of any fracture (p=0.11), there was no statistically significant interaction for any of 
the fracture outcomes.  Similar results were noted when FRAX probability was computed 
without BMD.  
Efficacy of abaloparatide-SC to decrease the risk of major osteoporotic fracture or any clinical 
fracture in postmenopausal women with low BMD and/or prior fracture appears independent  
of baseline fracture probability.  
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Introduction 
Abaloparatide-SC is a 34 amino acid peptide with 71% homology with PTHrP(1-34) and 41% 
homology to PTH(1-34) that has been developed for subcutaneous delivery in the treatment 
of osteoporosis in postmenopasual women (1,2).  In a phase III, randomised placebo-controlled 
trial, Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE), in ambulatory 
postmenopausal female patients with osteoporosis,  both abaloparatide-SC and teriparatide 
significantly decreased new vertebral fractures by 86% and 80%, respectively, whilst the 
relative risk reduction in nonvertebral fractures reached significance only for abaloparatide 
(43% vs. 28% for teriparatide) (3).  These effect sizes represent the average treatment effect 
and the question often arises if the effect is greater in sub-groups of patients with certain risk 
criteria.  Sub-group analyses, especially those undertaken post hoc, decrease the study power 
while increasing the risk of type 1 errors(4).  The use of analyses that examine for interactions 
using a continuous risk variable, such as baseline fracture probability, can reduce the impact 
of categorical sub-group analyses.   
FRAX (http://www.shef.ac.uk/FRAX), the computer-based tool for assessment of fracture 
probability in men and women, was primarily developed to identify patients for treatment.  
However, several recent analyses have explored the interaction of treatment efficacy with 
pre-treatment fracture probabilities as assessed by FRAX (5-8). For example, in post hoc 
analyses greater efficacy of treatment with increasing baseline FRAX fracture probability has 
been reported for clodronate (8), whereas no interaction has been observed with raloxifene 
and strontium ranelate (5,6).  More relevant, perhaps, are two recent studies of teriparatide 
that also showed similar efficacy of teriparatide across the range of baseline fracture 
probabilities whether the drug was administered daily or weekly (9,10).  The aims of the present 
analysis were two-fold: to characterise the baseline fracture risk of those entering the ACTIVE 
study and, to determine whether the efficacy of abaloparatide-SC was independent of 
baseline fracture probability. 
 
Methods 
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In the ACTIVE study, the effect of treatment (abaloparatide-SC 80mcg daily) on vertebral 
fracture incidence was compared to double-blind placebo or open-label treatment with 
subcutaneoaus teriparatide 20mcg daily(3).   The study subjects comprised women age 50 ?85 
years with a diagnosis of osteoporosis (BMD T-ƐĐŽƌĞ A?-2.5 and >-5.0 at the lumbar spine or 
femoral neck by DXA) and radiological evidence of two or more mild, or one or more moderate, 
vertebral fractures, or a history of low trauma forearm, humerus, sacral, pelvic, hip, femoral or 
tibial fracture within the past 5 years; women with more than four mild or moderate vertebral 
fractures or any severe vertebral fracture were excluded.  Women over 65 years of age who 
met the fracture criteria but had a BMD T-ƐĐŽƌĞA?-2.0 and >-5.0 were allowed to enroll. Women 
over 65 years of age who did not meet the fracture criteria but had a T-ƐĐŽƌĞA?-3.0 and >-5.0 
were also recruited. 
All relevant individual-level data were provided by Radius Health, Inc. to the authors for this 
independent analysis. Data were provided on 1645 women aged 49-86 years who received 
abaloparatide-SC or placebo, with information on the clinical risk factors used in FRAX available 
in all, except for a parental history of hip fracture.  Bone mineral density of the femoral neck at 
baseline was also available in 1642 patients.  Data on fracture outcomes (patients with incident 
fractures) and treatment allocation were also transferred.   
FRAX Assessment 
Ten-year fracture probability was assessed with the FRAX® tool (version 3.9) in all patients 
blinded to any outcome variable.  Both major osteoporotic fracture probability and hip fracture 
probability were chosen as risk variables.  The estimate of probability can be used with clinical 
risk factors alone, or with femoral neck BMD and both outputs were calculated.  The clinical risk 
factors included:   
A prior fragility fracture  ? this variable was a composite of prior nonvertebral fracture 
(excluding skull, feet and hands) and a semi-quantitative radiographic assessment of vertebral 
fractures at baseline (T4-L4).  Previous analyses of phase 3 studies have shown that grade 1 
vertebral fractures (11) are of no or limited prognostic value for nonvertebral fractures (12) .  A 
similar analysis undertaken in the ACTIVE confirmed this (Appendix); grade 1 fractures were 
therefore excluded in the base case analysis but were included in subsequent sensitivity 
analyses.   
5 
 
Parental history of hip fracture  ? this variable was not captured at entry to the study and was 
simulated based on examining the conditional probability of the association of a risk factor 
with age, BMI, and the dichotomous FRAX variables by logistic regression (13).   The 
associations were taken from the relationship between all clinical risk factors including BMI 
and femoral neck BMD in the cohorts with relevant information used to develop the FRAX 
model (14).  Baseline probabilities assuming a total absence of parental history of hip fracture 
(variable set to no for all participants) were used in the base case, but simulated values were 
included in sensitivity analyses. 
Current tobacco smoker  ? a positive answer to a question enquiring about smoking of 
cigarettes or tobacco in the last 5 years was accepted as representing current smoker, as 
included in FRAX. 
Ever long-term use of oral glucocorticoids  ? this was set to no for all participants as the use of 
oral glucocorticoids within the previous 12 months was an exclusion criterion for the study. 
Rheumatoid arthritis  ? this was captured as a distinct variable based on the medical history.   
Secondary osteoporosis - The presence of a cause of secondary osteoporosis was based on 
the medical history dataset and adjudicated by a study safety group.  Causes of secondary 
osteoporosis included type 1 diabetes mellitus (n=1), malnutrition (n=1), liver disorders 
(n=29) and premature menopause (n=83).  It should be noted that the secondary 
osteoporosis variable does not contribute to fracture probability when BMD is included in the 
calculation of FRAX.  While increasing evidence suggests type 2 diabetes is a fracture risk 
factor, it is not yet a formal secondary cause within FRAX and its inclusion would not have 
allowed an equitable comparison of baseline probabilities with other studies in the literature.  
A total of 181 women were recorded to have type 2 diabetes with comparable numbers (88 
and 93) in the placebo and abaloparatide-SC groups respectively.  
 
Daily alcohol consumption of 3 or more units ? ĂƉŽƐŝƚŝǀĞƌĞƐƉŽŶƐĞ ? ?zĞƐ ? ?ǁĂƐĂƐƐƵŵĞĚŝĨĂ
patient had answered the question  ?ŵŽƵŶƚŽĨĂůĐŽŚŽůŝĐĚƌŝŶŬƐƉĞƌǁĞĞŬ? ? with 21 or more 
units; all other values were set to "No". 
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Femoral neck BMD - BMD values were supplied as absolute BMD values from the scanner 
together with the manufacturer.  For BMD measured with Lunar Prodigy, the BMD was 
converted to Hologic values to remove the systematic differences between machine 
manufacturers (15).  A T-score was calculated using the NHANES reference values for young 
Caucasian women (16) as used in FRAX (14).  For 3 patients with missing BMD tests, probabilities 
were only calculated without the inclusion of BMD and were excluded from analyses where 
FRAX was computed with BMD.  
 
Country specificity - In addition to the dependence on clinical risk factors, fracture probability 
varies markedly in different regions of the world (17) so that the FRAX models are calibrated to 
those countries where the epidemiology of fracture and death is known.  FRAX models were 
available for all countries recruiting patients in the ACTIVE study.  These included Argentina, 
Brazil, Czech Republic, Denmark, Estonia, Hong Kong, Lithuania, Poland, Romania and the US 
(ethnic specific models were available and used for the US). 
 
Fracture outcomes - Depending on the skeletal site involved, incident fractures (regardless of 
the level of trauma) were variously categorized as any fracture (n=111), any osteoporotic 
fracture (excluding ankles, hands, feet, skull and face,  n=82), major osteoporotic fractures 
(n=67), clinical vertebral fractures (n=13) and vertebral fractures assessed by morphometry 
(n=40).  For the latter, it was assumed that the morphometric fractures had occurred half-way 
between the date of the x-ray finding and the prior x-ray.   
 
Analytic approach 
The effect of treatment was examined in an ITT analysis.  For these analyses, the base case 
excluded the family history simulations and also excluded grade 1 baseline vertebral fractures, 
thus representing a more conservative approach.  A Poisson model was used to study the 
relationship between age, the time since baseline, treatment, calculated 10-year probability 
on the one hand and on the other hand, the risk of fracture with only one fracture being 
counted per patient (18). Here the person years were used (in contrast to a linear logistic 
model). The hazard function was assumed to be exp(E0 + E1 · current time from baseline + E2  · 
current age + E3 · 10-year probability + E4 · treatment + E5 · 10-year probability · treatment). 
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The beta coefficients reflect the importance of the variables as in a logistic model, and Ex = 0 
denotes that the corresponding variable ĚŽĞƐŶŽƚĐŽŶƚƌŝďƵƚĞƚŽĨƌĂĐƚƵƌĞƌŝƐŬ ?dŚĞǀĂƌŝĂďůĞ ?10-
year probability  ?ƚƌĞĂƚŵĞŶƚ ?tested for an interaction between efficacy and baseline 10-year 
probability, handled as a continuous variable, by determining if E5>0.  Interactions other than 
10-year probability · treatment, such as T-score · treatment, previous fracture · treatment, age 
· treatment were explored in sensitivity analyses. 
Hazard ratios (HR) for treatment effect and 95% confidence intervals (95% CI) were computed 
as a continuous variable.  For presentation, hazard ratios were shown at the 10th, 25th, 50th, 
75th, and 90th percentile of fracture probability.   
 
Results 
Baseline characteristics and fracture probabilities 
The baseline characteristics of the placebo and abaloparatide-SC groups at entry to the ACTIVE 
study are shown in Table 1.  The mean probability of a major osteoporotic fracture, calculated 
with BMD, was 13.1% and 13.2% respectively in placebo and abaloparatide-SC arms.  Just over 
half (55%) of the participants had a major osteoporotic fracture probability greater than 10%, 
while 15% were greater than 20%.  The mean probability of a hip fracture was 4.7% and 4.9% 
respectively (Table 1).  Fifty seven percent of the participants had a hip fracture probability 
greater than 3%, while approximately one third (34%) were greater than 5%.  There were no 
significant differences among treatment arms concerning 10-year probability of hip or major 
osteoporotic fracture (p>0.20 for all comparisons).  
Replication of efficacy analysis of abaloparatide 
Compared to placebo, abaloparatide-SC decreased the risk of morphometric vertebral 
fractures by 86% - an effect that was statistically significant (Table 2).  A similar reduction was 
observed on clinical vertebral fractures (88% reduction).  Treatment was also associated with 
a significant 43% reduction in the risk of any clinical fracture, an effect that was enhanced 
when the analysis was confined to osteoporotic clinical fractures and major osteoporotic 
fractures (Table 2).   
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Interaction between treatment and FRAX fracture probability  
In Table 3, the effects of abaloparatide-SC on the various categories of fracture outcomes 
according to the 10-year probability of a major osteoporotic fracture are shown where the 
baseline probability has been entered as a continuous variable in the model, which reduces 
the variance around the estimates. Note that clinical vertebral fractures are included in all the 
outcomes in Table 3 apart from the category of morphometric vertebral fractures.  Confidence 
estimates for the hazard ratio crossed unity at all probabilities for clinical vertebral fractures.  
In contrast, the confidence estimates for the hazard ratio were at or well below unity across 
the range of probabilities for morphometric vertebral fractures.  For all outcomes, hazard 
ratios tended to decrease (i.e., greater efficacy) with increasing fracture probability.  Whereas 
the interaction approached significance for the outcome of any fracture (p=0.11), there was 
no statistically significant interaction for any of the fracture outcomes.  The interaction 
between treatment effect and fracture probability for the outcome of major osteoporotic 
fracture is shown in Figure 1.  Similar conclusions about interactions in the continuous models 
were derived when the simulated variables were included and/or when grade 1 vertebral 
fractures were included (data not shown).  The interaction between treatment effect and 
fracture probability for the outcome of major osteoporotic fracture, based on tertile of 
baseline probability, is shown in Table 4.  The sub-group analysis shows reductions in all 
tertiles but with wide confidence intervals and no significant interaction (p>0.30).   
Suggested threshold fracture probabilities for inclusion into clinical trials by CHMP criteria are 
given as 15-20% for vertebral fracture, 5-7.5% for hip fracture and 10-15% for major non-
vertebral fractures.  In the case of hip fracture probability, more than one third of the women 
(34-37%, depending on whether probability calculated with BMD and/or simulated variables) 
recruited to the ACTIVE study exceeded the threshold risk of 5% with, as expected, a smaller 
proportion (18-21%) exceeding a threshold risk of 7.5%.  For major osteoporotic fracture 
probability, 57% of the women lay over the threshold of 10% and 32% over the threshold of 
15%.  At a threshold of 10% and higher, there was a clear significant reduction in major 
osteoporotic fractures during abaloparatide-SC therapy (Figure 1). 
Sensitivity analyses including other interactions (e.g. T-score · treatment, previous fracture · 
treatment, age · treatment) or the inclusion of the simulated history of parental fracture or 
grade 1 vertebral fractures had no significant impact on the results. 
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Discussion 
It is an increasing trend, given the need for placebo-controlled registration studies, that the 
baseline fracture probabilities of recent studies are low when compared to earlier phase 3 
studies in osteoporosis (Table 5).  For example, at the 50th percentile of the distribution, the 
probability of a major osteoporotic fracture in the ACTIVE study was similar to that seen in the 
study of bazedoxifene (7) but was somewhat lower than in studies of teriparatide (9,10), 
clodronate (8), strontium (5) and raloxifene (6).  Notwithstanding, abaloparatide-SC therapy was 
associated with a significant reduction in fracture risk that was similar across a wide range of 
fracture probabilities; this implies that the intervention has efficacy in women at high risk, a 
requirement of the Committee for Medicinal Products for Human Use (CHMP) guidance (19).  
The latter proposes thresholds of major osteoporotic fracture probability between 10-15% for 
clinical trial inclusion and it is clear from Figure 1 that abaloparatide is associated with 
significant fracture risk reduction in individuals with fracture risk at or above these values.   
The findings from the present study can be placed within the context of retrospective 
assessments of other phase III studies.  In a 3-year prospective, randomized, placebo-
controlled trial of oral clodronate (20), women aged 75 years or more living in the general 
community were given 800mg oral clodronate or matching placebo daily over three years.  
Greater clinical osteoporotic fracture reduction was seen at higher fracture probabilities, with 
or without the use of BMD, and efficacy was evident at fracture probabilities that exceeded 
20% (8).  Similar findings of greater efficacy at higher probabilities, though without significant 
interactions, have been reported in analyses of the phase III studies of bazedoxifene (21) and 
denosumab (22).  As in the case of clodronate, hazard ratios for the effect of bazedoxifene on 
all clinical fractures decreased with increasing fracture probability (7), such that in patients with 
10-year fracture probabilities at or above 16%, bazedoxifene was associated with a significant 
decrease in the risk of all clinical fractures (7).  In a pre-planned analysis of the FREEDOM trial, 
greater efficacy against fracture was shown in individuals at higher risk treated with 
denosumab (22).  In contrast, other studies have not shown this trend and, similar to 
abaloparatide-SC, have shown similar efficacy across a range of fracture probabilities (with 
greater absolute risk reductions in those at higher risk) (5,6,9,10).  For example, in a similar 
analysis of alendronate efficacy in the FIT trials, there was no evidence of an interaction 
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between alendronate and baseline major osteoporotic fracture probability (with FN BMD) for 
the risk of non-vertebral fracture, clinical fractures, major osteoporotic fractures, and 
radiographic vertebral fractures(23).  Nonetheless, the absolute benefit of alendronate was 
greatest among women with highest baseline fracture probability by FRAX. 
This analysis has a number of strengths and limitations.  The inclusion criteria for the study 
mean that it is difficult to generalize the observation of no apparent interaction to women 
with higher BMD or different fracture profiles.  The fracture event rates are relatively low so 
that the power of the analysis to detect significant interactions is also reduced.  For example, 
if a significant interaction for the outcome of any fracture existed between abaloparatide-SC 
efficacy and baseline fracture probability, then the observed p-value (p=0.11) suggests that we 
would need a 3.1 fold increase in the cohort size to show significance (p<0.05) at a power of 
80% if everything (fracture rates, effect size and interaction etc) remained as reported in the 
current study.  However, It is clear that our method of analysis, i.e. avoiding post hoc 
subgroup analysis by using a continuous variable such as FRAX probability, is a better 
approach than the use of categorical subgroups where the power to detect interaction is 
lower but paradoxically the chance of false positive results in sub-groups is higher (24).   
The lack of capture of information on a parental history of hip fracture meant that this 
variable had to be handled in a number of ways.  Simulation was used to ensure that a 
potential history of parental hip fracture contributed to our estimate of the baseline risk 
profile of the study.  Importantly, the use of the simulated population or the setting of 
ƉĂƌĞŶƚĂůŚŝƐƚŽƌǇƚŽ ?ŶŽ ?ĨŽƌĂůůƉarticipants, did not impact on the conclusions drawn.  This 
reflects the fact that the omission of parental history, or indeed the inclusion/exclusion of 
grade 1 vertebral fractures, is unlikely to bias any interactions between efficacy and fracture 
probability since the decision is likely to affect the placebo and treatment wings of the study 
equally.   
In summary, despite a relatively low fracture incidence , the present analysis of the phase 3 
ACTIVE study of abaloparatide-SC in postmenopausal women with low BMD and/or prior 
fracture shows efficacy of abaloparatide-SC for all fracture outcomes compared to placebo, 
with apparently similar efficacy across a wide range of baseline fracture risk.   
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Table 1   Baseline characteristics and ten-year probability (%) for hip fracture and a major 
osteoporotic fracture at entry to the ACTIVE study for the placebo and abaloparatide-SC 
groups, calculated with and without BMD.  Values are means±SD, unless stated otherwise. 
 
Characteristic Placebo Abaloparatide-SC P-valuea 
Number 821 824  
Age (y) 68.7±6.5 68.9±6.5 NS 
BMI (kg/m2) 25.1±3.6 25.0±3.5 NS 
Prior fracture (%) 57 58 NSa 
Parental hip fracture (%)b 6 6 NSa 
Glucocorticoid use (%)c 0 0 - 
Rheumatoid arthritis (%)c 0 0 NSa 
Smoking (%) 11 13 NSa 
Alcohol (%) 0 0 NSa 
Secondary osteoporosis (%) 4 5 NSa 
Femoral neck BMD T-score -2.15±0.68 -2.16±0.63 NS 
FRAX MOF probability (no BMD) (%) 13.1 ± 7.7 13.4 ± 8.5 NS 
FRAX Hip probability (no BMD) (%) 5.0 ± 4.3 5.3 ± 5.3 NS 
FRAX MOF probability (+ BMD) (%) 13.1 ± 7.7 13.2 ± 8.1 NS 
FRAX Hip probability (+ BMD) (%) 4.7 ± 4.4 4.9 ± 5.0 NS 
a Fishers permutation test; b Simulated for estimation of baseline probabilities only;  
c Presence excluded patients from the trial; NS Not statistically significant 
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Table 2.  Overall effects of abaloparatide-SC compared to placebo according to the fracture 
outcome selected.  As described in the analytical approach, the analysis used a Poisson model. 
Fracture outcome 
Overall treatment effect 
(HR, 95%CI) 
Two-sided 
p-values 
Any clinical fracture 0.57, 0.36-0.91 0.019 
Osteoporotic fracture 0.39, 0.21-0.70 0.0018 
Major osteoporotic fracture 0.31, 0.15-0.62 0.001 
Clinical vertebral fracture 0.12, 0.01-0.92 0.041 
Morphometric vertebral 
fracture 
0.14, 0.05-0.39 <0.001 
 
 
15 
 
 
Table 3.  Hazard ratio between treatments (abaloparatide-SC versus placebo) for all clinical, osteoporotic, major osteoporotic fractures, clinical 
and morphometric vertebral fractures at different values of 10-year probability (%) of a major osteoporotic fracture calculated with BMD. 
Percentile 10-year 
probability 
(%) 
Any clinical 
fracture 
Osteoporotic 
fracture 
Major osteoporotic 
fracture 
Clinical vertebral 
fracture 
Morphometric 
vertebral fracture 
10th 4.70 0.89 (0.45, 1.79) 0.49 (0.20, 1.19) 0.46 (0.16, 1.30) 0.21 (0.01, 5.13) 0.22 (0.05, 1.02) 
25th 6.87 0.80 (0.44, 1.45) 0.46 (0.21, 1.01) 0.42 (0.17, 1.02) 0.19 (0.01, 3.18) 0.20 (0.05, 0.75) 
50th 10.53 0.65 (0.40, 1.07) 0.42 (0.22, 0.80) 0.35 (0.17, 0.74) 0.16 (0.02, 1.62) 0.16 (0.05, 0.49) 
75th 15.51 0.50 (0.30, 0.84) 0.38 (0.20, 0.70) 0.28 (0.13, 0.60) 0.12 (0.02, 1.00) 0.13 (0.04, 0.39) 
90th 22.36 0.34 (0.15, 0.78) 0.32 (0.13, 0.79) 0.20 (0.06, 0.67) 0.09 (0.01, 1.37) 0.09 (0.02, 0.49) 
p-value for 
interaction* 
 0.11 >0.30 >0.30 >0.30 >0.30 
*Two-sided p-value for interaction between treatment and FRAX 
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Table 4.  Number of incident major osteoporotic fractures and hazard ratios between 
treatments (abaloparatide-SC versus placebo), classified by tertiles of baseline major 
osteoporotic fracture probability (MOF), calculated with BMD. 
 
Tertiles of MOF 
probability 
N N with incident 
fractures 
HR (95% CI) 
<8.47 547 10 0.27 (0.06-1.28) 
8.47-14.26 548 12 0.44 (0.13-1.46) 
>14.26 547 22 0.27 (0.09-0.79) 
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Figure 1   Impact of abaloparatide-SC on major osteoporotic fracture compared to placebo, 
expressed as hazard ratio, across the range of major osteoporotic fracture probabilities at 
baseline.  The interaction of efficacy with baseline probability was not significant (p>0.30).    
 
  
18 
 
 
Table 5.  Summary of intervention studies that have examined the distribution of FRAX 
probabilities of a major fracture calculated with BMD (studies ranked by median probability) 
Intervention Percentile Reference 
 10 25 50 75 90  
Bazedoxifene 2.8 4.5 8.2 14.5 21.7 (7) 
Abaloparatide-SC 4.7 6.9 10.5 15.5 22.4 ACTIVE study 
Clodronate 10 12 16 22 30 (8) 
Denosumab 7.9 11.0 16.2 23.2 32.3 Johansson** 
Teriparatide 8.5 12.2 17.6 24.4 32.6 (9) 
Raloxifene 8.4 13.3 21.1 30.3 40.1 (6) 
Strontium 11.5 16.0 22.2 30.2 39.8 (5) 
Teriparatide* 13.7 18.8 25.4 31.8 39.0 (10) 
Alendronate 14.2 - 27.7 - 49.1 (23) 
*Weekly administration, **Personal communication 
 
 
